Zoladex as Primary Therapy in Advanced Pro static Cancer A French Cooperative Trial

Metz, R; Namer, M.; Adenis, L; Audhuy, B.; Bugat, R.; Colombel, P; Couette, J.E.; Grise, P.; Khater, R.; LePorz, B.; Levin, G.; Marti, Pierre; Mauriac, M.; Rouxel, A.; Tetelboum, R.

doi:10.1097/00000421-198801102-00027

Cited by 17 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,7,16 Endocrinologic side effects of LHRH agonists have been reported to produce a decrease in libido (92%), impotence (86%), hot flushes (48%) and breast swelling or tenderness (9%); 17 however, such side effects of this widely used agent have not been fully investigated, partly because of feasibility problems and physicians' doubts as to the value of such efforts, especially for aged patients with advanced prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone‐releasing hormone agonist therapy

1999

View full text Add to dashboard Cite

Background: Luteinizing hormone-releasing hormone (LHRH) agonists have been widely used as effective agents in endocrine therapy for prostate cancer. Continuous administration of the drug results in profound suppression of testicular androgen production. However, the side effects on erectile function have not been fully investigated. Methods:We studied the influences of testosterone suppression on male sexual function and nocturnal penile tumescence in nine sexually active patients with prostate cancer who were treated with an LHRH agonist.Results: Following reduction of serum testosterone concentrations to a castration level by the administration of the LHRH agonist, sexual desire, sexual interest and sexual intercourse were totally annulled, with significant changes in frequency, magnitude, duration and rigidity of nocturnal erections observed in all patients.Conclusions: These results demonstrate that the LHRH agonist strongly suppresses erectile function and sexual activity. Taking into account the quality of sexual function for relatively young and sexually active patients and their partners, it is necessary to establish effective modalities that minimize the adverse effects on sexual function for the treatment of patients with prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone‐releasing hormone agonist therapy

1999

View full text Add to dashboard Cite

show abstract

“…This results in a reduction of almost all of the body's testosterone Drug B is given by tablet and taken once a day. It works by blocking the effects of the hormone testosterone at the site of the prostate cancer Both treatments have side-effects; some side-effects are specific to one drug and some are shared by both drugs Side-effects shared by both drugs Side-effects shared by both drugs Reduced ability to have an erection in nine out of ten men 9,26 Reduced ability to have an erection in two out of ten men 12,13 Decreased sexual interest in nine out of ten men 9,26 Decreased sexual interest in two out of ten men 12,13 Hot flushes in seven out of ten men 27 Hot flushes in one out of ten men 18 Weight gain -infrequently Weight gain -infrequently Nausea, vomiting and diarrhoea -infrequently Nausea, vomiting and diarrhoea -infrequently Hair loss -infrequently…”

Section: Which Of the Two Treatments Would You Choose Based On The Fomentioning

confidence: 99%

Preferences of hxealthy men for two different endocrine treatment options offered for locally advanced prostate cancer

Jenkins

Fallowfield

Edginton

et al. 2005

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…Anabolic steroids may suppress endogenous steroid production, thereby possibly leading to ED on withdrawal. Administration of LHRH agonists has been reported to produce decreased libido in 92% of patients and ED in 86% of patients 40 …”

Section: Drug Therapymentioning

confidence: 74%

Aging and erectile dysfunction: The role of aging and concomitant chronic illness

Marumo

Murai

2001

Int J of Urology

View full text Add to dashboard Cite

Erectile dysfunction (ED) can have a strong negative effect on the well-being and quality of life of the sufferer. Many factors may contribute to the development of this disorder; age in particular and also concomitant chronic illnesses including neurological, hormonal, arterial and cavernosal factors. An understanding of the prevalence and characteristics of risk factors for ED is required, in order to establish effective therapeutic strategies. However, the prevalence of ED depends on the definitions used and the use of an internationally established scale for the assessment of male sexual function is necessary to facilitate the comparison of data between different countries.Further epidemiologic research and analysis of individual risk factors is required. Such studies will clarify the interactive effects of organic factors and their probable etiology with the general physical, sociocultural and psychologic status of patients. These efforts will make it possible to design more effective future strategies for the treatment and prevention of ED.

show abstract

Zoladex as Primary Therapy in Advanced Pro static Cancer A French Cooperative Trial

Cited by 17 publications

References 0 publications

Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone‐releasing hormone agonist therapy

Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone‐releasing hormone agonist therapy

Preferences of hxealthy men for two different endocrine treatment options offered for locally advanced prostate cancer

Aging and erectile dysfunction: The role of aging and concomitant chronic illness

Contact Info

Product

Resources

About